May 19, 2020
Nine internationally recognized experts join Sustainability Council
- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2020
- Events
- Inside Information
- Latest Inside Information
- Archive Overview
- Inside Information 2019
- Inside Information 2018
- Inside Information 2017
- Ad-hoc 2016
- Ad-hoc 2015
- Ad-hoc 2014
- Ad-hoc 2013
- Ad-hoc 2012
- Ad-hoc 2011
- Ad-hoc 2010
- Ad-hoc 2009
- Ad-hoc 2008
- Ad-hoc 2007
- Ad-hoc 2006
- Ad-hoc 2005
- Ad-hoc 2004
- Ad-hoc 2003
- Ad-hoc 2002
- Ad-hoc 2001
- Ad-hoc 2000
- Ad-hoc 1999
- Ad-hoc 1998
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2019
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Investor News
May 13, 2020
Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
moreMay 11, 2020
Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
moreApril 28, 2020
CEO Werner Baumann at the Bayer AG Annual Stockholders' Meeting:
"We're active in the right businesses"
moreApril 27, 2020
First quarter of 2020:
Bayer: Good start to 2020 - activities marked by COVID-19
moreMarch 30, 2020
Not intended for U.S. and UK Media
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer
moreMarch 29, 2020
Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:
Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery
moreMarch 28, 2020
Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology's 69th Annual Scientific Session together with World Congress of Cardiology
Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularization
moreMarch 28, 2020
Not intended for U.S. and UK Media - Data from Phase III VICTORIA study presented at American College of Cardiology's 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC)